The IJPH series “Young Researcher Editorial” is a training project of the Swiss School of Public Health
Cannabis use and dependence is a rising public health challenge worldwide. Globally, the number of people with cannabis use disorder and its associated burden of diseases have notably increased in the past decades, particularly affecting young people [, ]. Despite this rising burden, public health responses remain limited.
While there are no established pharmacological treatments for cannabis use and dependence, psychosocial approaches, including motivational and cognitive-behavioral interventions, may improve cannabis use outcomes []. However, access to these treatments remains limited by workforce, time and transportation barriers. Treatment-related stigma, shaped by histories of drug control and enforcement that unevenly affect underserved populations, also discourages formal help-seeking []. Moreover, existing interventions are rarely delivered when people need support most and are often minimally responsive to changing risk states and individual needs. In this context, recent advances in artificial intelligence (AI) create an opportunity to address these gaps by making cannabis interventions more accessible, scalable, timely, and personalized.
AI conversational chatbots are one promising approach. In practice, chatbots could be engineered to deliver core elements of psychosocial interventions for cannabis use by helping users set goals, identify triggers, strengthen motivation, and practice coping and relapse-prevention skills. A recent systematic review of chatbot-assisted substance use interventions, mainly for tobacco and alcohol use, found that experimental studies reported meaningful effects on substance use outcomes and users generally found the interventions useful and acceptable []. Importantly, chatbots could address existing access gaps by providing private, on-demand support outside conventional clinic settings and extending services to people facing geographic, transportation, scheduling, or stigma-related barriers. They could scale up at exceptionally low marginal costs, reducing reliance on scarce trained professionals.
AI could also improve the timeliness of cannabis use interventions through just-in-time adaptive interventions (JITAIs). JITAIs can use machine learning methods to identify moments of heightened vulnerability and trigger support in a timely manner, although evidence of their effectiveness for substance use remains limited []. For cannabis use, this could involve drawing on self-reported data, prior engagement patterns, time, location, or other digital signals to identify vulnerable moments, such as craving after work, social exposure to use, boredom at night, or stress after conflict. The intervention could then provide a real-time response, such as a motivational message, coping prompt, or brief cognitive-behavioral exercise. Because cannabis use risk is often episodic and context-dependent, JITAIs could complement psychosocial approaches by delivering their content at high-risk moments rather than only in scheduled or user-initiated sessions.
Conversational chatbots and JITAIs could be combined in intervention design. In such a model, the JITAI component identifies moments of heightened risk using self-reported, behavioral, or contextual data, while the chatbot delivers support in a conversational format, which could be personalized to adapt to the user’s current state. For example, a recent smoking-cessation intervention integrated JITAI with a generative chatbot and was evaluated favorably by a domain expert [].
While direct evidence remains limited, certain elements of psychosocial interventions for tobacco use may be adaptable to cannabis interventions, as these substances overlap in psychosocial processes such as motivation, cravings, triggers, coping, and relapse. This possibility is supported by evidence that cannabis co-users who reduced cigarette use in a smoking cessation intervention may concurrently reduce their cannabis use, even though cannabis use was not explicitly addressed []. Therefore, existing evidence on tobacco interventions [, ] could support the feasibility of AI-enabled cannabis use interventions. Nevertheless, adaptation would be required to account for the unique characteristics of cannabis use, including diverse products and routes of administration, self-medication, associations with social identity, and legal status.
Above all, innovative AI interventions for cannabis use must be designed with safety and privacy as core requirements. A review found over half of health-related chatbots failed to respond adequately to high-risk messages such as suicidal thoughts []. Such limitations may become particularly consequential in cannabis interventions, where users may experience psychotic symptoms or other crises. AI systems also raise privacy concerns because they may collect sensitive behavioral data, infer vulnerability, and transmit information across systems that users do not fully understand []. Depending on the jurisdiction, intervention data may be subject to compelled disclosure in legal or administrative proceedings. Systems should therefore have a clearly limited clinical scope, minimize data collection and retention, clearly explain any limits of confidentiality, and provide reliable escalation pathways to human support.
In summary, AI approaches could substantially extend the reach of psychosocial support for cannabis use and warrant more sustained research. Design, development and evaluation of innovative AI interventions should extend beyond a focus on efficacy to considerations of whether these tools improve engagement and reduce access and stigma-related barriers without safety or privacy concerns. Future implementation research should identify which populations benefit or remain underserved, establish reliable pathways to human care, and examine how effective innovations can be integrated into routine care and public health infrastructure.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
YH conceptualized and wrote this editorial.
Conflict of interest
The authors declare that they do not have any conflicts of interest.
Generative AI statement
The author(s) declared that generative AI was used in the creation of this manuscript. Parts of this manuscript were edited with the assistance of ChatGPT; it is use only to check spelling, grammar and clarity of expression.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
References
1.
ShahKFarwaUEVanapartiAPatelSKanumuriMVashishthOet alGlobal epidemiology of cannabis use disorders and its trend from 1990 to 2019: benchmarking analysis of the global burden of disease study. J Fam Med Prim Care (2024) 13(3):881–9. 10.4103/jfmpc.jfmpc_824_23
2.
ShaoHDuHGanQYeDChenZZhuYet alTrends of the global burden of disease attributable to cannabis use disorder in 204 countries and territories, 1990-2019: results from the disease burden study 2019. Int J Ment Health Addict (2024) 22:2485–507. 10.1007/s11469-022-00999-4
3.
HalickaMParkhouseTLWebsterKSpigaFHinesLAFreemanTPet alEffectiveness and safety of psychosocial interventions for the treatment of cannabis use disorder: a systematic review and meta-analysis. Addiction (2025) 120(11):2181–201. 10.1111/add.70084
4.
LazorTMehraKRupJWieseJLWatsonTMHamiltonHet alNavigating mental health and cannabis use post-cannabis legalization: experiences from racialized community members. Contemp Drug Probl (2026) 53(3):567–86. 10.1177/00914509251394526
5.
LeeSYoonJChoYChunJ. A systematic review of chatbot-assisted interventions for substance use. Front Psychiatry (2024) 15:1456689. 10.3389/fpsyt.2024.1456689
6.
PerskiOHébertETNaughtonFHeklerEBBrownJBusinelleMS. Technology-mediated just-in-time adaptive interventions (JITAIs) to reduce harmful substance use: a systematic review. Addiction (2022) 117(5):1220–41. 10.1111/add.15687
7.
BosschaertsKKashefiADe MarezLConradiePVan HoeckeSOngenaeF. Designing a just-in-time adaptive intervention with trigger detection and a generative chatbot: smoking cessation use case. Digit Health (2025) 11:20552076251381747. 10.1177/20552076251381747
8.
NguyenNNeilandsTBLishaNELyuJCOlsonSSLingPM. Longitudinal associations between use of tobacco and cannabis among people who smoke cigarettes in real-world smoking cessation treatment. J Addict Med (2022) 16(4):413–9. 10.1097/ADM.0000000000000920
9.
XueJZhangBZhaoYZhangQZhengCJiangJet alEvaluation of the current state of chatbots for digital health: scoping review. J Med Internet Res (2023) 25:e47217. 10.2196/47217
10.
LiJ. Security implications of AI chatbots in health care. J Med Internet Res (2023) 25:e47551. 10.2196/47551
Summary
Keywords
artificial intelligence, cannabis use, chatbots, just-in-time adaptive interventions, psychosocial intervention
Citation
Hu Y (2026) Chatbots and beyond: transforming cannabis use interventions with innovative AI approaches. Int. J. Public Health 71:1609866. doi: 10.3389/ijph.2026.1609866
Received
10 April 2026
Revised
10 October 2026
Accepted
13 October 2026
Published
26 October 2026
Volume
71 - 2026
Edited by
Germán Guerra, National Institute of Public Health, Mexico
Reviewed by
One reviewer who chose to remain anonymous
Updates
Copyright
© 2026 Hu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yuqi Hu, y7hu@ucsd.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.